It is now recognized that the low-grade inflammation observed with obesity is associated with the development of a wide range of downstream complications. As such, there is considerable interest in elucidating the regulatory mechanisms underlying the production of inflammatory molecules to improve the prevention and treatment of obesity and its co-morbidities. White adipose tissue is no longer considered a passive reservoir for storing lipids, but rather an important organ influencing energy metabolism, insulin sensitivity and inflammation by the secretion of proteins, commonly referred to as adipokines. Dysregulation of several adipokines, such as tumor necrosis factor-alpha (TNF-a), interleukin-6 (IL-6) and adiponectin, contributes to the low-grade inflammation that is a hallmark of obesity. Evidence now suggests that fatty acids represent a class of molecules that can modulate adipokine production, thereby influencing inflammatory status. Although the precise molecular mechanisms by which dietary fats regulate adipokine production remain unclear, recent findings indicate that diet-gene interactions may have an important role in the transcriptional and secretory regulation of adipokines. Single-nucleotide polymorphisms in the genes encoding TNF-a, IL-6 and adiponectin can modify circulating levels of these adipokines and, subsequently, obesity-related phenotypes. This genetic variation can also alter the influence of dietary fatty acids on adipokine production. Therefore, the current review will show that it is paramount to consider both genetic information and dietary fat intake to unravel the interindividual variability in inflammatory response observed in intervention protocols targeting obesity.
Introduction
Obesity is a chronic low-grade inflammatory state that is associated with an increased risk for cardiovascular disease, diabetes, metabolic syndrome and a number of cancers (Maury and Brichard, 2010) . Although trends suggest that the obesity epidemic may have plateaued in Western countries, our understanding of the genetic and molecular network underlying this metabolic disease remains incomplete (Bessesen, 2008) . Hundreds of genes are known to have minor contributions in defining the obese phenotype; however, our current lack of understanding of the numerous gene-gene and gene-environment interactions underlying obesity poses one of the major obstacles for the development of effective preventative and therapeutic intervention strategies. In addition, lifestyle factors such as diet and exercise also have important roles in modifying the onset, development and severity of obesity and obesity-related complications. Therefore, the observed clinical and molecular heterogeneity in the obese phenotype that can vary both within and across populations stems from genetic, lifestyle and behavioral factors.
Simply stated, obesity is characterized by the accumulation of lipid in white adipose tissue (WAT). The WAT is a specialized connective tissue composed of a number of different cell types each with specific functions. Adipose tissue can be roughly divided into two fractions: the adipocyte fraction (AF) and the stroma vascular fraction (SVF). The AF is composed of mature adipocyte cells that are primarily involved in lipid storage, thereby having a major role in the regulation of whole-body energy homeostasis (DiGirolamo et al., 1998) . In contrast to the cellular homogeneity of the AF, the SVF is composed of numerous cell types, including preadipocytes, mesenchymal stem cells, macrophages, endothelial cells and fibroblasts-all of which can play a role in regulating adipose tissue inflammation (Nair et al., 2005) .
Indeed, obese WAT was previously shown to be infiltrated by numerous types of inflammatory cells, and may promote the increase in extracellular components and fibrotic regions seen in adipose tissue biopsies from obese patients (Mutch et al., 2009b; Divoux et al., 2010) . Furthermore, it is now appreciated that WAT is an important endocrine organ, in which both the AF and SVF secrete molecules, referred to as adipokines. It is worth mentioning that the term adipokine was originally proposed to describe proteins secreted specifically from the adipocyte (Trayhurn and Wood, 2004) ; however, as many cell types in adipose tissue have been found to secrete proteins, the term adipokine is now widely used to describe proteins secreted from adipose tissue . This article considers adipokines using the latter definition. Adipokines have been shown to influence a wide range of biological functions, such as immunity, insulin sensitivity, inflammation, blood pressure, lipid metabolism, energy homeostasis and appetite (Trayhurn and Wood, 2004 ). To date, over 100 adipokines have been cataloged and more adipokines continue to be discovered using new technologies and innovative approaches (Shah et al., 2009; Mutch et al., 2009a; Kim et al., 2010) .
Owing to the influence of adipokines throughout the biological system, identifying factors that regulate their secretion has become a primary interest in obesity research . Dietary fatty acids (FA) are one class of compounds that have garnered considerable attention for their ability to regulate adipose tissue metabolism and secretory function (Oller do Nascimento et al., 2009) . Although the molecular mechanisms by which dietary fats regulate adipokine production remain unclear, one proposed link between dietary FA and inflammation may be via the toll-like receptor 4 (TLR4) pathway, a link recently discussed in a review by Fessler et al. (2009) . Briefly, TLR4 is expressed in both omental and subcutaneous adipose tissue (AT), and has been shown to be activated by saturated fatty acids (SFA), inducing inflammatory cytokine production and signalling (Fessler et al., 2009) . This results in a localized inflammation in adipose tissue that propagates an overall systemic inflammation (Shi et al., 2006; Poulain-Godefroy et al., 2010) . WAT inflammation in general is associated with the development of obesity-related co-morbidities, such as cardiovascular disease and type 2 diabetes. More specifically, enlarged adipocytes coupled with macrophage infiltration result in the increased secretion of pro-inflammatory adipokines that favor lipolysis leading to ectopic lipid accumulation as well as a disruption in glucose and insulin signalling pathways throughout the body (Gustafson, 2010; Karastergiou and Mohamed-Ali, 2010; Momiyama et al., 2010) .
The aim of this review is to outline the current state of knowledge with regard to the interactions between dietary FA and three adipokines that mediate obesity-related inflammation: tumor necrosis factor-alpha (TNF-a), interleukin-6 (IL-6) and adiponectin. It is important to recognize that a large number of inflammation-related adipokines have been identified to date, including but not limited to complement-like factors, chemokines, acute phase proteins and adhesion factors (Karastergiou and Mohamed-Ali, 2010) ; however, the current review will focus on the three aforementioned adipokines as proof-of-principle examples showing the link between FA-gene interactions, adipokines and obesity. Emerging research now shows that dietary FA and single-nucleotide polymorphisms (SNPs) in the genes encoding TNF-a, IL-6 and adiponectin can interact to regulate their production and secretion, thus adding an additional level of complexity in the study of obesity. Taken together, this review will illustrate that nutrigenomics research can provide a more thorough understanding of how changes in dietary FA intake may contribute to the inter-individual variability in inflammatory status observed in intervention protocols.
Tumor necrosis factor-a TNF-a and obesity TNF-a is a pro-inflammatory cytokine whose expression and circulating levels are increased with obesity and decreased with weight loss (Maury and Brichard, 2010) . TNF-a has numerous effects in adipose tissue, including the regulation of apoptosis, adipogenesis, lipid metabolism and insulin signalling (Prins et al., 1997; Galic et al., 2010) . The primary cell type responsible for the production of TNF-a are macrophages in the SVF (Trayhurn and Wood, 2004) . It is hypothesized that TNF-a is produced by macrophages in response to chemoattractant signals released by dying adipocytes. Evidence suggests that TNF-a triggers a signalling cascade that induces cell apoptosis, which may be one mechanism by which TNF-a regulates adipose tissue mass (Prins et al., 1997; Cawthorn et al., 2007) . Another TNF-a-mediated mechanism that may work in parallel to regulate adiposity involves the regulation of key transcription factors controlling adipogenesis, such as peroxisome proliferator-activated receptors (PPAR)-g2 and CCAAT enhancer-binding protein-a (C/EBPa) (Cawthorn et al., 2007) . Although such effects suggest that increases in TNF-a may be beneficial, TNF-a has also been shown to induce inflammatory pathways and contribute to obesity-related insulin resistance.
An increase in TNF-a promotes the secretion of other pro-inflammatory cytokines and reduces anti-inflammatory cytokines, resulting in an overall pro-inflammatory state. For example, a study conducted by Wang and Trayhurn (2006) found that treating human adipocytes with TNF-a for 24 h led to significant decreases in adiponectin expression and increases in IL-6 and TNF-a expression. TNF-a has also been found to increase the production of plasminogen activator inhibitor-1, an adipokine linked to cardiovascular disease (Cawthorn and Sethi, 2008) . Taken together, these examples show that TNF-a is a powerful regulator of inflammatory molecules, favoring an overall inflammatory state (Wang and Trayhurn, 2006) .
Increased TNF-a also promotes insulin resistance by the inhibition of the insulin receptor substrate 1 signalling pathway. It is believed that TNF-a interferes with insulin signalling by deregulating protein kinases, which subsequently affects the phosphorylation status of insulin receptor substrate-1, leading to an inability of insulin receptor substrate-1 to associate with the insulin receptor (Kanety et al., 1995; Hotamisligil et al., 1996) . Antibody neutralization studies with TNF-a resulted in a significant increase in glucose uptake in response to insulin (Hotamisligil et al., 1993) . Moreover, whole-body deletions of TNF-a or its receptors were found to increase insulin sensitivity and glucose tolerance (Uysal et al., 1997) . Taken together, these works show a critical role for TNF-a in the regulation of obesity-related pathways.
Genetic variation affecting TNF-a signalling Recent evidence suggests that individual SNPs in the genes encoding TNF-a, TNF-a receptor 2 and TNF-a-converting enzyme can modify an individual's risk for obesity and obesity-related complications. One aspect that has not yet been studied is whether a haplotype consisting of SNPs in the three aforementioned genes will have an additive or synergistic effect on these complications.
Several polymorphisms have been identified in the promoter region of TNF-a. A recent meta-analysis by Sookoian et al. (2005) described the impact of the best characterized TNF-a polymorphism (À308G/A; rs1800629) on obesity. The À308G/A polymorphism was shown to increase the transcriptional activity and production of TNF-a (Wilson et al., 1997) . Sookoian et al. (2005) examined data from 31 observational studies and concluded that the À308G/A variant was positively associated with obesity (odds ratio of 1.23). Moreover, fasting insulin concentrations were significantly higher in A carriers than in homozygotic GG carriers. Another promoter SNP (À238G/A; rs361525) may also be associated with body fat, insulin resistance and circulating free FA (Fontaine-Bisson et al., 2007) . Although the mechanisms by which these promoter variants affect circulating TNF-a levels remain unclear, their significant association with obesity and insulin levels reinforce the importance of conducting further studies.
TNF-a interacts with two cell-surface receptors: TNF-a receptor 1 and receptor 2. The TNF-a receptor 2 is associated with obesity, as shown by the increase in TNFR2 gene expression and its positive correlation with TNF-a expression as body weight increases (Good et al., 2006) . Furthermore, TNFR2 is located in a chromosomal region previously linked to obesity-related phenotypes (Chagnon et al., 1997) . The first study exploring the effect of genetic variation in TNFR2 was recently performed in individuals from Caucasian nuclear families. Twelve SNPs were examined and one SNP (rs5746059) was associated with obesity-related parameters. Individuals with the A allele had a 4.6% higher fat mass and a 2.5% increase in percentage fat mass in relation to noncarriers (Zhao et al., 2008) . These associations were subsequently replicated by the authors in a different ethnic population (the Chinese Han), suggesting that the association between TNFR2 and body weight is independent of ethnicity. Future work should focus on determining whether genetic variation in TNF-a receptors can modify TNF-a signalling and its downstream functions.
ADAM17 encodes the TNF-a-converting enzyme protein, which is responsible for cleaving and releasing TNF-a from cells (Black et al., 1997) . Similar to the TNF-a and TNFR2 genes, the expression of ADAM17 and the secretion of its protein product are increased with obesity (Voros et al., 2003) . Recently, six SNPs were genotyped in subjects participating in the Genetics of Lipid-Lowering Drugs and Diet Network study and two SNPs, ADAM17_m1254A4G (rs11684747) and ADAM17_i33708A4G (rs10495563), were associated with obesity-related phenotypes (Junyent et al., 2009) . Carriers of the G allele in m1254A4G exhibited a higher risk of obesity and had higher insulin levels. Individuals homozygous for the A allele in i33708A4G had a higher risk of obesity and a higher waist circumference than GG carriers (Junyent et al., 2009) .
Taken together, genetic variation can modify TNF-a signalling and subsequently alter obesity-related phenotypes, including body fat mass, insulin sensitivity and potentially the secretion of other adipokines. Moreover, genetic variation in the various players involved in TNF-a signalling may provide a partial explanation with regard to the high degree of inter-individual variability observed with obesity-related phenotypes.
TNF-a and dietary FAs
Research using in vitro and in vivo mouse models have shown that TNF-a expression is differentially regulated by FA (Table 1) . Using 3T3-L1 adipocytes, palmitic acid (C16:0) was found to increase TNF-a gene expression and protein secretion in a dose-dependent manner (Bradley et al., 2008) . In contrast, oleic (C18:1n-9) and docosahexaenoic acids (DHA; C22:6n-3) had no affect on TNF-a expression or secretion (Bradley et al., 2008) . Mice that consumed a high fat diet for 5 weeks showed increases in TNF-a expression; however, the concomitant administration of eicosapentaenoic acid (EPA; C20:5n-3) prevented this increase (Perez-Matute et al., 2007) . In another study, mice fed menhaden fish oil showed a reduced expression of TNF-a in kidneys (Chandrasekar and Fernandes, 1994) . When considered altogether, these studies indicate that SFA increase and n-3 polyunsaturated FA (PUFAs) decrease TNF-a expression and/or secretion.
Importantly, these murine results appear to translate to human beings (Table 2) . Subjects consuming a fish oil supplement showed a significant decrease in TNF-a production; however, levels of TNF-a returned to baseline upon cessation of the supplements (Endres et al., 1989) . This was confirmed in another study where subjects who ingested a-linolenic acid (C18:3n-3) for 4 weeks had a 30% reduction in TNF-a production. When these subjects were further supplemented with fish oil, TNF-a synthesis was inhibited by up to 70% (Caughey et al., 1996) . Finally, men who consumed fish oil supplements for 12 weeks showed differential decreases in TNF-a production in accordance with their pre-supplementation levels (Grimble et al., 2002) .
In addition to the independent influences of genetic variation and different FA on the TNF-a signalling pathway, research discovering diet-gene interactions offers a further explanation for the inter-individual variability observed with 
Mice feeding studies Male C57Bl6 mice fed ad lib one of four high fat diets enriched with either 17.5% (by weight) n-6 PUFA (soybean oil), n-3 PUFA (fish oil), SFA (coconut oil) or MUFA (lard) for either 2 days (acute treatment) or 60 days (chronic treatment)
High fat diets k in WAT in acute treatment groups with all diets k in WAT in n-6 PUFA and SFA chronic treatment groups k in all high fat diet groups for acute treatment k in n-6 PUFA, SFA and MUFA chronic treatment groups Bueno et al. (2008) Male C57BL/6J mice fed ad lib EPA/DHA concentrate containing 6% EPA and 51% DHA, 5 weeks
Rat feeding studies Zucker diabetic fatty (fa/fa) rats fed CLA diet supp. with 5% corn oil and 1% CLA (46.0% of 9c, 11t; 47.3% of 10t, 12c; 3.2% of 9c, 11c/10c, 12c; and 0.4% of 9t, 11t/10t, 12t), 8 weeks
Abbreviations: CLA, conjugated linoleic acid; DA, lauric acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; FA, fatty acid; IL, interleukin; LA, linoleic acid; MUFA, monounsaturated fatty acid; OA, oleic acid; PA, palmitic acid; PUFA, polyunsaturated fatty acid; SFA, saturated fatty acid; TNF, tumor necrosis factor; WAT, white adipose tissue; m/k, an increase/decrease.
obesity-related inflammatory status (Table 3 ). For example, Grimble et al. (2002) found that men with one A allele at the À308 loci and who were in the highest tertile for TNF-a production had the most significant reduction in TNF-a levels after supplementation with fish oil in comparison to homozygotic G/G men. No conclusions could be made about À308A/A individuals owing to the small sample size. Junyent et al. (2009) found that the association between the A allele in ADAM17_i33708A4G and obesity was only seen in individuals with a low n-6 PUFA intake. In another study by Fontaine-Bisson and El-Sohemy (2008) , a low n-6 PUFA intake in subjects who were homozygous for G at the À238 loci and had at least one A (that is, GA or AA) at the À308 loci had an increased risk of developing obesity; however, another study found that carriers of at least one A allele at À308G/A who had a large intake of n-6 PUFAs had an increased risk of developing obesity (Nieters et al., 2002) . Taken together, these newly discovered dietÀgene interactions that affect TNF-a signalling are an important point to consider in future intervention studies targeting obesityrelated inflammation.
Interleukin-6
IL-6 and obesity IL-6 is an inflammatory cytokine produced and secreted from WAT (Eder et al., 2009) . In obesity, circulating 
Intervention study
Supp. normal diets with flaxseed oil (56% a-LNA, 18% LA) and flaxseed oil and butter spread (23% a-LNA, 8% LA) for 8 weeks. At week 4, diets were supp. with nine fish oil capsules (1.62 g EPA, 1.08 g DHA) per day Abbreviations: AA, arachidonic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; FA, fatty acid; GLA, g-linolenic acid; IL, interleukin; LA, linoleic acid; a-LNA, a-linolenic acid; MUFA, monounsaturated fatty acid; PA, palmitic acid; PUFA, polyunsaturated fatty acid; SFA, saturated fatty acid; TNF, tumor necrosis factor; m/k, an increase/decrease.
Diet-gene interactions and adipokines C Stryjecki and DM Mutch
concentrations of IL-6 are elevated and weight loss leads to a decrease in its levels (Vozarova et al., 2001; Bougoulia et al., 2006) . Approximately 30% of circulating IL-6 is derived from adipose tissue (Galic et al., 2010) . Although adipocytes are capable of producing and secreting IL-6, it is believed that they only contribute a fraction of the IL-6 produced by adipose tissue (Eder et al., 2009) . Indeed, it has been shown that cells of the adipose tissue SVF secrete more IL-6 than fully differentiated adipocytes (Harkins et al., 2004) . The primary source of circulating IL-6 are macrophages that have infiltrated WAT, which contribute up to 50% of the IL-6 produced by adipose tissue (Eder et al., 2009) . Other sources of IL-6 include activated leukocytes and endothelial cells (Harkins et al., 2004) .
Functionally, IL-6 is involved in the regulation of inflammation, hematopoiesis, immune responses and host defense mechanisms (Eder et al., 2009) . Furthermore, it is capable of regulating both body weight and lipid metabolism (Mohamed-Ali et al., 1997) . Both in vitro and in vivo studies have confirmed that IL-6 is capable of suppressing lipoprotein lipase activity, leading to a decrease in adipose triglyceride accumulation (Greenberg et al., 1992) . IL-6 and its receptors are also expressed in several regions of the brain, such as the hypothalamus, and have been shown to contribute to the regulation of appetite and energy intake (Stenlof et al., 2003) . Taken together, this shows that IL-6 has important roles in the regulation of whole-body energy homeostasis and inflammation. Genetic variation affecting IL-6 signalling Several studies have reported associations between IL-6 gene variants and obesity-related phenotypes, such as adiposity, insulin resistance and dyslipidemia; however, much of the existing data are conflicting. The À174G/C SNP (rs1800795), located in the IL-6 promoter region, is the most commonly studied polymorphism and has been shown to influence IL-6 expression and secretion levels . As discussed in the preceding section, IL-6 expression and circulating levels are increased in obesity; however, studies examining the association between IL-6 polymorphisms and body mass index (BMI) have generated inconsistent results. A meta-analysis by Huth et al. (2009) provided the most comprehensive and recent report with regard to the association between the À174G/C SNP and BMI. Integrating data from 15 studies conducted in Caucasian populations (corresponding to B24 000 subjects) revealed no statistically significant association between this promoter SNP and BMI. This study confirmed an earlier meta-analysis by Qi et al. (2007b) , who examined over 26 000 subjects from across 19 studies to examine the association between the À174G/C SNP and BMI. Although 6631 subjects were in common between the two meta-analyses, both studies failed to associate the À174G/C allele with BMI. However, the study by Qi et al. (2007b) examined an additional five SNPs in IL-6 (rs2069827, rs1800797, rs1554606, rs2069861 and rs1818879) and identified a haplotype that was significantly associated with both waist circumference and BMI, suggesting that genetic variability in the IL-6 gene may affect adiposity.
Interestingly, smaller studies suggest that variance in the À174G/C SNP may partially explain the inter-individual variability reported in various parameters measured during weight management protocols. For example, Poitou et al. (2005) genotyped 65 obese subjects for the À174G/C SNP, and measured circulating IL-6 levels before and 1 year after gastric banding surgery. Patients homozygous for the C allele had increases in IL-6 levels post-surgery, whereas G carriers had decreases. In an alternate study of weight loss following gastric banding surgery, homozygous carriers of the G allele lost significantly more weight than GC or CC subjects (Sesti et al., 2005) . This suggests that GG carriers may respond more favorably to gastric surgery interventions (that is, better decreases in both body weight and inflammation). Goyenechea et al. (2006) found that subjects who regained less than 10% body weight in the year following a weight loss period were predominantly carriers of the C allele, suggesting that variation in the IL-6 gene may also influence successful weight maintenance. Finally, Klipstein-Grobusch et al. (2006) found that subjects homozygous for the C allele reported 'significantly larger recalled weight gain from age 25 to study enrolment' compared with homozygous G allele subjects in the EPIC-Potsdam Study. As the À174G/C SNP was not associated with adiposity in the aforementioned meta-analyses, it is highly possible that the results of these smaller studies may be insignificant when examined in larger cohorts. Nevertheless, these studies suggest that it is important to clarify whether variability in the IL-6 gene is associated with adiposity and whether this may play a role in optimizing personalized weight management programs.
IL-6 signalling pathways are triggered upon interaction with the ubiquitously expressed gp130 receptor and the IL-6 receptor alpha (IL-6Ra). Although genetic variation in IL-6Ra
has not yet been specifically studied in the context of obesity, recent studies examining the association between SNPs in IL-6Ra and type 2 diabetes suggest that such research is warranted. The IL-6Ra gene maps to a region that has been consistently linked to type 2 diabetes (Kristiansen and Mandrup-Poulsen, 2005) . Focused studies suggest that genetic variation in IL-6Ra is capable of modulating diabetes risk. Hamid et al. (2004) determined that the non-synonymous IL6R þ 48867C/A (rs8192284) SNP, which leads to an Asp358Ala variant, was associated with diabetes risk; however, Qi et al. (2007a) found that while this variant was significantly associated with plasma IL-6 levels, they did not find an association with diabetes risk. Although evidence linking type 2 diabetes to the aforementioned SNP is conflicting, it shows that variation in IL-6Ra may influence the development of diabetes and should be further examined. Further examination of the rs8192284 SNP in relation to IL-6 levels is also required.
These results show that SNPs in IL-6 and/or IL-6Ra can affect circulating levels of IL-6, obesity and obesity-related complications. Therefore, elucidating the impact of genetic variation in the IL-6 signalling pathway may lead to improved strategies for health management in obese individuals.
IL-6 and dietary FAs
The ability of n-3 PUFA to attenuate inflammatory responses is widely recognized; however, details with regard to the modulation of IL-6 levels remain unclear. In vitro studies revealed that treatment of 3T3-L1 adipocytes with palmitic acid increased IL-6 mRNA and protein levels in culture media (Table 1) , and induced NF-kb activity, whereas DHA and lauric acid (C12:0) had no effect (Ajuwon and Spurlock, 2005) . Interestingly, when adipocytes were simultaneously treated with DHA and palmitic acid, NF-kb activation was attenuated without affecting IL-6 mRNA abundance, suggesting that independent mechanisms may mediate the DHA regulation of NF-kb activation and IL-6 production (Ajuwon and Spurlock, 2005) . Similarly, the pretreatment of human macrophages with either EPA or DHA decreased LPS-stimulated IL-6 mRNA levels and production (Weldon et al., 2007) . Furthermore, both EPA and DHA led to a significant reduction in NF-kb activity, implying that pathways triggered by n-3 PUFAs may vary between the different cell types in adipose tissue.
Several studies using mouse models reinforced cell culture observations (Table 1) . When mice were fed one of two high fat diets consisting of either soybean oil or palmitic acid, the mice that consumed palmitic acid showed a threefold increase in IL-6 expression in adipose tissue (Davis et al., 2008) . These results parallel another study in which adipocytes from rats were analyzed following the consumption of an SFA-enriched diet and were found to release the most IL-6 (Garcia-Escobar et al., 2010) . In contrast, rats fed a MUFA diet released the least amount of IL-6 from adipocytes, showing that dietary FA can differentially regulate both IL-6 expression and secretion in vivo. The conclusions made from cell culture and animal studies appear to apply to human beings as well.
A cross-sectional study conducted in men from the MultiEthnic Study of Atherosclerosis cohort revealed that increased n-3 PUFA intake and fish consumption was associated with decreased plasma concentrations of IL-6 and other inflammatory markers (He et al., 2009) (Table 2) . Such results were similarly observed by (Ferrucci et al. 2006) , who found that lower levels of arachidonic acid (20:4n-6) and DHA were associated with higher levels of IL-6. Interestingly, different classes of FA appear to have distinct effects on IL-6 production and/or signalling pathways. The 8-week consumption of an SFA-enriched diet resulted in a pro-inflammatory phenotype, which was not observed following the consumption of an MUFA-enriched diet. Furthermore, microarray analysis in adipose tissue found that the SFA diet upregulated 17 and 20 genes related to the IL-6 and NF-kb signalling pathways, respectively (van Dijk et al., 2009 ). This significant enrichment of inflammatory gene signalling was not observed in the adipose tissue of subjects who consumed the MUFA diet.
Although to our knowledge no studies yet have examined the interactions between IL-6 polymorphisms and FA intake, and their impact on obesity-related phenotypes, a recent study of Crohn's disease suggests that such research will generate important insight for understanding whether diet can modulate the obese phenotype in relation to IL-6 variation. Guerreiro et al. (2009) examined the role of the IL-6 À174G/C SNP, fat intake and the risk of developing Crohn's disease. Individuals homozygous for the C allele had a sixfold higher risk for Crohn's disease. Furthermore, these individuals also showed an interaction between SFA and MUFA consumption and disease risk. This result suggests that dietary fat intake may interact with IL-6 variants to affect the low-grade inflammation characterizing obesity.
Adiponectin
Adiponectin and obesity Adiponectin is an anti-inflammatory adipokine expressed solely in mature adipocytes and is the most abundantly secreted protein from adipose tissue (Lihn et al., 2004; Qi et al., 2006) . In human beings, adiponectin gene expression is lower in visceral adipose tissue compared with subcutaneous adipose tissue, regardless of body weight, suggesting that the latter fat depot plays a predominant role in regulating circulating adiponectin levels (Lihn et al., 2004) .
Adiponectin regulates lipid and glucose metabolism, stimulates FA oxidation, suppresses gluconeogenesis, increases insulin sensitivity, protects against chronic inflammation and regulates food intake and body weight ). The biological effects of adiponectin are mediated by two receptors, adiponectin receptor 1 and adiponectin receptor 2 (ADIPOR1 and ADIPOR2, respectively). The ADIPOR1 gene is ubiquitously expressed, whereas ADIPOR2 is expressed mainly in skeletal muscle and the liver in human beings (Kadowaki and Yamauchi, 2005) . Despite the ADIPORs being widely expressed, the liver is believed to be the primary site of adiponectin bioactivity where it: (1) increases FA oxidation through the activation of AMP-activated protein kinases, and (2) decreases hepatic glucose output by downregulating enzymes involved in gluconeogenesis (Combs et al., 2001; Yamauchi et al., 2002; Trujillo and Scherer, 2005) .
Adiponectin levels are reduced in animal models of obesity and insulin resistance (Fumeron et al., 2004) , and weight loss has been shown to increase adiponectin levels (MorenoNavarrete et al., 2010). The reduction of adiponectin is also associated with a decrease in lipid oxidation, increased triglycerides and a suppression of insulin-dependent signalling in the liver and muscle, all of which can contribute to insulin resistance and obesity . Human studies show that hypoadiponectinemia is associated with insulin resistance, hyperinsulinemia and the possibility of developing type 2 diabetes, independent of fat mass (Fumeron et al., 2004) . Furthermore, the expression of both ADIPORs was shown to be significantly decreased in the skeletal muscle of diabetic subjects, suggesting that in obesity and diabetes subjects, a reduction in ADIPOR will further diminish adiponectin's actions (Potapov et al., 2008) .
Genetic variations affecting adiponectin signalling
Adiponectin is found on chromosome 3q27, a region that has been linked to susceptibility for metabolic syndrome, type 2 diabetes and cardiovascular disease (Kyriakou et al., 2008) . Adiponectin is highly polymorphic, with associations having been found between SNPs, circulating levels of adiponectin, obesity and obesity-associated co-morbidities (Table 3) . Kyriakou et al. (2008) reported that the þ 276G/T (rs1501299) SNP in the adiponectin gene is significantly associated with elevated fasting serum adiponectin levels in two independent cohorts of healthy, Caucasian females. Further investigation is required to determine whether this association holds true in men, as adiponectin plasma levels differ significantly between men and women (Nishizawa et al., 2002) . Conversely, Kondo et al. (2002) and Razquin et al. (2009) showed a negative association between the þ 276G/T SNP, adiponectin plasma levels and BMI. Homozygotic carriers of the G allele with a high BMI had lower adiponectin plasma levels, whereas homozygotic carriers of the T allele displayed higher weight gain in response to a Mediterranean-style dietary intervention. In addition, it was shown that obese homozygote carriers of the G allele had decreased serum adiponectin levels relative to obese G/T and T/T carriers (Gonzalez-Sanchez et al., 2005) . Razquin et al. (2009) also showed that another SNP in the adiponectin gene, þ 45T/G (rs2241766), is associated with body weight, in which individuals with the GG genotype gained the most weight over the study period.
The þ 276G/T SNP is also believed to be associated with some of the risk factors for obesity and metabolic syndrome. A negative association was found between adiponectin levels and waist-to-hip ratios, abdominal diameter, triglycerides and insulin resistance (Gonzalez-Sanchez et al., 2005) . These results suggest that SNPs in the adiponectin gene are potential markers for predicting obesity and its complications; however, results are conflicting. For example, some studies suggest that the þ 45T/G and þ 276G/T SNPs can act as markers for type 2 diabetes, whereas other research reports that these SNPs are poor or weak markers for the disease. A European study determined that only the þ 45T/G SNP was associated with type 2 diabetes and the þ 276G/T SNP was only associated with type 2 diabetes in subjects who were also obese (Gable et al., 2007) . As such, the researchers concluded that adiponectin SNPs are poor markers for predicting the development of type 2 diabetes (Gable et al., 2007) .
Genetic variation in the adiponectin promoter region has also been shown to influence circulating adiponectin levels and body weight. The major allele of the À10066G/A (rs182052) SNP and the minor alleles of À11391G/A (rs17300539) and À7734C/A (rs16861209) were significantly associated with elevated fasting serum adiponectin levels in healthy women (Kyriakou et al., 2008) . Similar associations were found in the Genetics of Lipid-Lowering Drugs and Diet Network study; adiponectin concentrations were found to be higher in the À11391A individuals but lower in À11377G (rs266729) individuals (Warodomwichit et al., 2009) . A significant association was found between the À11391G/A SNP and obesity traits, in which À11391A carriers had significantly lower weight, BMI and waist-and-hip circumferences (Warodomwichit et al., 2009) . Goyenechea et al. (2009) also found significant associations between the À11391G/A SNP, adiponectin levels and body weight.
Variation in ADIPORs has also been associated with obesity-related complications, such as type 2 diabetes and insulin resistance. In a study involving type 2 diabetic patients and non-diabetic controls, the T allele of þ 219A/T (rs11061971) and the A allele of þ 795G/A (rs16928751), both located in ADIPOR2, were independently associated with an increased risk for type 2 diabetes (Potapov et al., 2008) . In contrast, the haplotype consisting of the þ 219A allele and the þ 795G allele was associated with a decreased risk of type 2 diabetes (Potapov et al., 2008) . Double homozygous diabetic patients (A/A and G/G) in this study had increased insulin sensitivity and decreased serum triglycerides, suggesting that this particular haplotype offers protection from the development and progression of type 2 diabetes (Potapov et al., 2008) . However, other studies have found contradictory results with regard to the associations between ADIPOR and type 2 diabetes. Another study found no association between SNPs in ADIPOR1 and type 2 diabetes and only a mild association between SNPs in ADIPOR2 and type 2 diabetes (Vaxillaire et al., 2006) . These conflicting results indicate that there are other interactions, both genetic and environmental, which are influencing an individual's risk for type 2 diabetes.
Adiponectin and dietary FAs
Rodent models have shown the effects of FA on adiponectin expression and protein levels (Table 1) . When Zucker diabetic fatty rats were fed a diet enriched with a mixture of conjugated linoleic acid isomers, an increase in both WAT adiponectin mRNA and plasma adiponectin levels was seen (Nagao et al., 2003) . An increase in adiponectin expression and plasma levels were detected in the mature adipocytes of mice fed ad libitum a high fat diet enriched with EPA and DHA (Flachs et al., 2006) . A recent study by Bueno et al. (2008) also showed that not only can adiponectin levels be influenced by FA, but that FA concentration can also affect depot-specific adiponectin expression. More specifically, mice were fed one of four high fat diets enriched with soybean oil, fish oil, coconut oil or lard for either 2 or 60 days. After 2 days of consuming the high fat diets, increased serum adiponectin levels were reduced in all high fat diet groups, but to a lesser extent in the fish oil group (Bueno et al., 2008) . Adiponectin expression was also reduced in retroperitoneal WAT in all dietary groups after 2 days. In mice consuming the diets for 60 days, a reduction in adiponectin expression was observed in epididymal adipose tissue of mice fed the soybean and coconut oil diets (Bueno et al., 2008) . When 3T3-L1 adipocytes were treated with palmitic acid, linoleic acid (C18:2n-6), EPA and DHA, a decrease in adiponectin was also observed after 48 h (Bueno et al., 2008) .
In humans, circulating adiponectin levels have been associated with plasma FA composition. For example, a negative association was observed between palmitic acid and adiponectin levels ( Table 2 ), suggesting that increased SFA plasma concentrations are associated with a decrease in circulating adiponectin (Fernandez-Real et al., 2005) . This decrease in adiponectin may in turn coincide with the proinflammatory affects of SFA (Fernandez-Real et al., 2005) . Furthermore, individuals with increased circulating levels of g-linolenic acid (C18:3n-6) had decreased levels of plasma adiponectin (Fernandez-Real et al., 2005) . In contrast, individuals with the highest proportions of n-3 PUFA, in particular DHA, had the highest levels of circulating adiponectin (Fernandez-Real et al., 2005) . This result is parallel to other human studies showing that supplementation with DHA and EPA decreased cytokine production, thus providing evidence for the anti-inflammatory properties of both n-3 PUFA and adiponectin (Fernandez-Real et al., 2005) . Moreover, these findings show the differential response of mice and human beings in response to n-3 PUFA.
In the Genetics of Lipid-Lowering Drugs and Diet Network study, associations between the À11391G/A SNP, BMI and obesity risk were modified by MUFA intake (Warodomwichit et al., 2009) . Carriers of the À11391A variant who had an MUFA intake exceeding the median MUFA intake (that is, X13% of energy intake) had a lower BMI and reduced risk for developing obesity (Warodomwichit et al., 2009) ; however, this association was not seen in individuals with an MUFA intake less than 13% (Warodomwichit et al., 2009) . Similar results were obtained by a Spanish group who wanted to determine the effects of a Mediterranean-style diet on adiponectin SNPs and weight changes over a 3-year period (Razquin et al., 2009) . As mentioned previously, the þ 45G/G and þ 276T/T genotypes were associated with higher weight gain over a 3-year period; however, the Mediterranean diet reversed these effects (Razquin et al., 2009) . Currently, the mechanisms by which dietary fats affect adiponectin levels are unclear; however, it is hypothesized that it may be through the activation of PPAR-g. FA such as EPA and DHA are ligands for PPAR-g, which subsequently upregulate adiponectin expression and circulating levels (Krey et al., 1997; Maeda et al., 2001) . These results show that particular classes of FA affect adiponectin levels, influencing an individual's predisposition for obesity and obesity-related inflammation.
Concluding remarks
Obesity is a highly heterogeneous phenotype, both at the clinical and the molecular levels. The various distinct stages in weight evolution (weight gain, weight loss and weight maintenance) will differentially affect an individual's risk for developing obesity-related complications. As shown with C-reactive protein (a common diagnostic marker for measuring inflammatory status), factors such as gender, age, fat distribution (that is, visceral AT vs subcutaneous AT) and lifestyle factors (for example, smoking, diet and exercise) are all able to independently and collectively influence the inflammatory state (Thorand et al., 2006; You and Nicklas, 2006; Clement and Langin, 2007; Stenholm et al., 2009 ). As such, the inflammatory status associated with the obese phenotype can be highly heterogeneous.
As evidenced in the preceding sections, the interactions between dietary lipids and genes coding for adipokines may help to further unravel the inter-individual variability that exists with regard to the obese phenotype. Although the precise molecular mechanisms linking FA and inflammation remain unclear, research with TLR4 suggests that the various classes of dietary FA (SFA, MUFA and PUFA; n-3, n-6 and n-9) most probably do not act via a single pathway. For example, Davis et al. (2008) found that SFA were able to induce TNF-a and IL-6 production in TLR4-null animals; despite the fact that TLR4-null mice had an overall improvement in inflammatory status. This suggests that dietary FA can affect the innate immune response, but that the molecular pathways linking dietary FA and adipokine production remain elusive.
Although elucidating the precise molecular pathways linking FA and adipokine production is not definitively resolved, the evidence discussed in this review reinforces the importance of unraveling these mechanisms to better understand the variability that exists with regard to inflammation in obese individuals, especially when one considers that WAT inflammation has been linked to obesity co-morbidities such as cardiovascular disease and type 2 diabetes. This review has focused on only three of the most commonly studied adipokines related to inflammation; however, evidence suggests that dietary FA may also affect other well-characterized adipokines such interleukin-10, serum amyloid A and monocyte chemotactic protein-1 (Bradley et al., 2008; Petersson et al., 2009; Yeop Han et al., 2010) . More than 100 adipokines have been characterized and their sensitivity to dietary FA has, for the most part, not been studied. As the physiological roles of these newly discovered adipokines become better understood and the variability in the genes underlying these secreted proteins is studied, the field of nutrigenomics is well positioned to begin clarifying how dietary FA can contribute to the chronic and mild inflammatory state associated with obesity.
